Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IOBT 
IO Biotech Inc (IOBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
- ALL
- 1Y
- 1M
Upturn Advisory Summary
12/02/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.46
1 Year Target Price $2.46
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.24% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.07M USD | Price to earnings Ratio - | 1Y Target Price 2.46 |
Price to earnings Ratio - | 1Y Target Price 2.46 | ||
Volume (30-day avg) 5 | Beta 0.46 | 52 Weeks Range 0.32 - 2.79 | Updated Date 12/2/2025 |
52 Weeks Range 0.32 - 2.79 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.345 | Actual -0.2498 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -88.58% | Return on Equity (TTM) -240.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36524110 | Price to Sales(TTM) - |
Enterprise Value 36524110 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 71948842 | Shares Floating 43401700 |
Shares Outstanding 71948842 | Shares Floating 43401700 | ||
Percent Insiders 5.15 | Percent Institutions 48.11 |
Upturn AI SWOT
IO Biotech Inc
Company Overview
History and Background
IO Biotech, Inc. is a clinical-stage biopharmaceutical company founded in 2015. They are focused on developing immune-oncology therapies targeting T-cell responses to treat cancer. Their focus is on IDO and TME.
Core Business Areas
- Immuno-oncology: Developing immune-oncology therapies targeting T-cell responses to treat cancer. The companyu2019s lead clinical programs are IO102-IO103.
Leadership and Structure
The leadership team includes Mai-Britt Zocca (CEO), and the company is structured around research and development, clinical trials, and corporate operations.
Top Products and Market Share
Key Offerings
- IO102-IO103: A combination therapy designed to suppress T-regulatory cells (Tregs) in the tumor microenvironment, enhancing the anti-tumor immune response. Currently undergoing clinical trials for various cancer types. Competitors include companies developing other Treg-targeting therapies and immune checkpoint inhibitors.
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, driven by the success of checkpoint inhibitors and the increasing understanding of cancer immunology. The market is competitive, with many companies developing novel immunotherapies.
Positioning
IO Biotech is positioned as an innovative player in the immuno-oncology space, focusing on novel targets within the tumor microenvironment. Their competitive advantage lies in their unique approach to Treg suppression.
Total Addressable Market (TAM)
The global immuno-oncology market is estimated to reach hundreds of billions of dollars. IO Biotech is positioned to capture a share of this market through successful development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting Tregs
- Strong preclinical and clinical data
- Experienced management team
- Focus on specific cancer types
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- No currently marketed products
- High R&D expenses
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer types
- Positive clinical trial results
- Market approval and commercialization of IO102-IO103
Threats
- Failure of clinical trials
- Competition from other immuno-oncology therapies
- Regulatory hurdles
- Patent disputes
Competitors and Market Share
Key Competitors
- MRNA
- BMY
- GILD
Competitive Landscape
IO Biotech faces competition from established pharmaceutical companies with broad immuno-oncology portfolios. Its advantage lies in its novel target (Tregs) and specific cancer focus.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's progress through clinical trials and expansion of its pipeline.
Future Projections: Future growth depends on the successful development and commercialization of IO102-IO103 and other pipeline candidates. Analyst estimates will reflect these developments.
Recent Initiatives: Recent initiatives include ongoing clinical trials, presentations at scientific conferences, and potential partnerships.
Summary
IO Biotech is a clinical-stage biotech company focusing on novel immune-oncology therapies. Its strength lies in its unique approach to Treg suppression, although it faces challenges from larger competitors and the inherent risks of clinical trials. Positive clinical trial results are critical for the company's success. They need to carefully manage financial resouces.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IO Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | Founder, President, CEO, Principal Financial Officer & Director Dr. Mai-Britt Zocca Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 80 | Website https://www.iobiotech.com |
Full time employees 80 | Website https://www.iobiotech.com | ||
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.